Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended July 31, 2000
Business Overview: The Company manufactures laboratory and technical products. Operations are divided into Laboratory Products and Technical Products segments.
Key Financial Metrics
| Metric | Q1 2001 (Ended July 31, 2000) | Q1 2000 (Ended July 31, 1999) |
|---|---|---|
| Net Sales | $19,370,000 | $20,065,000 |
| Gross Profit | $3,678,000 | $4,630,000 |
| Gross Margin | 19.0% | 23.1% |
| Operating Earnings | $397,000 | $1,361,000 |
| Net Earnings | $214,000 | $904,000 |
| Diluted EPS | $0.09 | $0.37 |
| Operating Cash Flow | $652,000 | ($672,000) |
| Capital Expenditures | ($907,000) | ($525,000) |
| Short-term Borrowings | $2,981,000 | $2,555,000 |
| Working Capital | $11,169,000 | $11,472,000 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3.5% to $19.4 million. This was driven by a decline in Laboratory Products sales due to softness in the industrial research market and a slowdown in new construction projects. Technical Products sales increased, partially offsetting the decline.
- Margin Compression: Gross profit margin fell from 23.1% to 19.0%. Management attributed this to an unfavorable product sales mix and increased employee medical costs.
- Operating Earnings Drop: Operating earnings declined significantly from $1.4 million to $397,000. This was exacerbated by production problems at the Statesville facility which delayed order completions.
- One-Time Items: The prior year included $140,000 in other income from a litigation settlement, whereas the current quarter recorded $15,000 in other expense.
- Inventory Buildup: Inventories increased by $1.4 million (from $3.5M to $4.9M), consuming cash flow despite a reduction in receivables.
Outlook, Risks, and Management Commentary
- Liquidity: The Company maintains a current ratio of 1.92-to-1. Management believes cash from operations and available credit facilities (revolving credit and equipment loans) are sufficient to support ongoing business and capital expenditures through the fiscal year.
- Debt Levels: Interest expense increased to $47,000 due to higher utilization of the revolving credit facility. Total short-term borrowings were $2.98 million at period end.
- Operational Risks: Management cited unexpected production problems at the Statesville facility as a factor delaying revenue recognition. Future results remain subject to economic and competitive factors affecting the industrial research market.
- Forward-Looking Statements: The filing includes a Safe Harbor statement noting that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the extent of the "softness" in the industrial research market and its projected duration.
- Confirm the resolution of production delays at the Statesville facility and their impact on future order fulfillment.
- Monitor the trend in inventory levels to ensure the $1.4 million increase does not signal obsolescence or demand weakness.
- Review the utilization of the revolving credit facility and the impact of rising interest rates on future interest expense.
- Assess the sustainability of the 19.0% gross margin given the cited mix changes and medical cost increases.